ozempic vs tirzepatide weight loss Ozempic® (semaglutide) and Mounjaro™ (tirzepatide), a major breakthrough for the treatment of obesity The Weight Loss Breakthrough Everyone's

Yatham LN, Schaffer A, Kessing LV, Miskowiak K, Kapczinski F, Vieta E, et al

Food and Drug Administration (FDA) approved Novo Nordisk's Wegovy pill as the first and only oral GLP-1 therapy indicated to reduce excess body weight, support long-term weight maintenance, and reduce the risk of certain major adverse cardiovascular events.1 FDA approval of the Wegovy pill was supported by a 64-week Phase 3 trial showing weight loss efficacy unmatched by other oral GLP-1 candidates, with once-daily treatment plus diet and exercise achieving 16.6% mean weight loss versus 2.7% with placebo.2 The availability of an oral formulation is expected to broaden access to GLP1 treatment by offering an alternative option for patients who may be hesitant to initiate or continue weekly injections

A 5mg vial reconstituted with 1ml of bacteriostatic water yields a concentration of 5mg/ml

Traditional in-person care can add $200 to $400 per month in visit and lab fees

Last Updated: March 2026 Many people use semaglutide to support weight loss and metabolic health